Aquatic Capital Management LLC Has $696,000 Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA)

Aquatic Capital Management LLC increased its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 327.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 79,917 shares of the company's stock after buying an additional 61,217 shares during the quarter. Aquatic Capital Management LLC owned 0.10% of Kura Oncology worth $696,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in KURA. Virtus ETF Advisers LLC lifted its holdings in shares of Kura Oncology by 71.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after purchasing an additional 3,061 shares in the last quarter. Harbor Advisors LLC acquired a new position in shares of Kura Oncology in the fourth quarter valued at approximately $87,000. E Fund Management Co. Ltd. bought a new stake in shares of Kura Oncology during the fourth quarter worth $90,000. Optimize Financial Inc acquired a new stake in shares of Kura Oncology during the fourth quarter worth $100,000. Finally, Corient Private Wealth LLC bought a new stake in Kura Oncology in the 4th quarter valued at $109,000.

Kura Oncology Price Performance

Kura Oncology stock traded down $0.07 during mid-day trading on Wednesday, reaching $5.73. 293,339 shares of the company were exchanged, compared to its average volume of 1,462,263. The company has a fifty day simple moving average of $6.67 and a 200-day simple moving average of $9.42. The firm has a market cap of $462.45 million, a PE ratio of -2.43 and a beta of 0.50. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology, Inc. has a 12 month low of $5.41 and a 12 month high of $23.48.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The company had revenue of $14.11 million for the quarter, compared to analyst estimates of $39.08 million. As a group, equities research analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on KURA shares. HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of Kura Oncology in a research note on Monday, April 28th. Wedbush reaffirmed an "outperform" rating and set a $36.00 price target on shares of Kura Oncology in a research note on Tuesday, April 8th. JMP Securities reissued a "market outperform" rating and issued a $28.00 price objective on shares of Kura Oncology in a research report on Tuesday, April 29th. StockNews.com lowered shares of Kura Oncology from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Finally, UBS Group decreased their price objective on Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $23.89.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.